Big Pharma Wants 'Data Exclusivity', India Says No In Trade Talks: Here's What This Means For Your Medicine Bill
As India negotiates trade deals with other countries, one demand keeps coming back to the table — that drug regulators be barred, for a fixed number of years, from approving cheaper copies of a new medicine, even after i
Ni Himani Chandna··194K nabasa
Big Pharma Wants 'Data Exclusivity', India Says No In Trade Talks: Here's What This Means For Your Medicine Bill
As India negotiates trade deals with other countries, one demand keeps coming back to the table — that drug regulators be barred, for a fixed number of years, from approving cheaper copies of a new medicine, even after its patent has expired.
The clause is called “data exclusivity”, and India has so far refused it. So far India has held its ground. It refused the UK’s demand for the clause in the free trade agreement announced on May 6, 2025. It had earlier turned down the same demand from the European Free Trade Association (EFTA) bloc of Iceland, Liechtenstein, Norway and Switzerland. The demand keeps returning, however, as India negotiates trade pacts with other partners.
“I am very clear in my mind that the demands being made by the developed world for data exclusivity are completely misplaced. They go against access to affordable medicine, and India has so far been resisting them,” said Abhijit Das, former Head and Professor, Centre for WTO Studies, Indian Institute of Foreign Trade (IIFT).
Das, who has participated directly in many multilateral and FTA negotiations, including the World Trade Organisation (WTO) Doha Round and OECD Steel Subsidies negotiations, told News18 that the clause is not good for patient access. He said developed countries are bullying other countries into accepting it, and that the consumer ultimately pays the price.
Experts told News18 the timing is delicate. About 55 blockbuster drugs, worth an estimated $300 billion, are expected to go off-patent worldwide over the next seven years.
What does the clause do?
To understand it, start with the patent. A company that patents a new medicine gets a monopoly for 20 years, counted from the day it files the application. During this time, no one else can make or sell the medicine without its permission, so the company decides the price. Once the 20 years end, anyone can make the medicine, and the generic versions that follow sell at a fraction of the original price, Das explained. For cancer and diabetes drugs, he described the drop as shocking. When Novo Nordisk’s patent on semaglutide, the molecule in Ozempic and Wegovy, expired in India on March 20, 2026, at least five Indian drugmakers launched generic versions within days, undercutting the original price by up to 80 per cent.
A patent alone does not put a medicine on the shelf. The maker must also get the country’s drug regulator’s approval, which rests on clinical trials showing the medicine is safe and works. In India, the regulator is the Central Drugs Standard Control Organisation (CDSCO). Because patent examination takes time, approval usually comes around the 12th or 13th year after the patent is filed, Das said, so the maker enjoys sole sale of the medicine for roughly seven to eight years.
A generic maker in India does not have to repeat the trials. It only has to show that its version behaves the same way in the body as the original, a test called bioequivalence. Das gave two reasons for this. “Giving dummy pills to patients in a trial for a copy of an already-approved medicine would be unethical, and repeating the trials would make medicines costlier and slower to reach people. The regulator keeps the innovator’s trial data confidential and does not show it even to the generic maker, but it uses the data to check the generic once bioequivalence is shown.”
How does data exclusivity change everything?
Data exclusivity bars the regulator from relying on the innovator’s trial data for a fixed period, so generic approvals cannot be given during that time, even after the patent ends. Das gave an example. Suppose approval comes in the 14th year after the patent is filed and the country grants five years of data exclusivity. That period ends in year 19, before the patent runs out, so nothing changes. With ten years, it ends in year 24, so generics would stay out for four years after the patent expires. “It will not be called patent protection, but it will be continuing your monopoly position in the market,” Das said. The actual length of the period would be set in any trade deal.
India and the developed world read the same international rule differently, experts claim. Article 39.3 of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement under the World Trade Organisation requires countries to protect trial data from disclosure and from unfair commercial use. Das said India meets both tests: “The TRIPS Agreement nowhere mandates this. This is an interpretation of the developed world,” he said. “Essentially, Article 39.3 is about confidentiality, not about exclusivity.” The US and Switzerland, among others, read it as exclusivity, he said.
Why do patients stand to lose?
The cost falls on the person buying the medicine every month. When cheaper versions are kept out, the patient has no lower-priced option to switch to, and in a market where most people pay out of pocket, that decides whether treatment continues.
KM Gopakumar, health laws researcher and co-convener of the Working Group on Access to Medicines and Treatment, which works closely alongside the public health network Jan Swasthya Abhiyan (JSA), said this is where the harm lands, and that the consumer is the one who ultimately loses.
He said companies are luring governments with the promise of more investment in return for such clauses. “New drugs usually debut in wealthy countries and reach India later, a decision driven by pricing and commercial strategy. India is among the world’s lowest-priced pharmaceutical markets and is seldom a first-launch country. Launches here are held back by the lack of reimbursement in a self-pay market, not by regulation or data rules.”
The Risdiplam — drug to treat spinal muscular atrophy (SMA) — case shows how much competition matters. Following a patent battle, a cheaper version of this drug for spinal muscular atrophy, a serious genetic condition, entered India, and its price reportedly fell by 97 per cent. Under data exclusivity, such an entry could have been held back even after the patent fight was won.
Innovation versus access
The pharmaceutical industry, which calls the protection regulatory data protection (RDP), says the clause would help India, not hurt it. Amitabh Dube, country president and managing director, Novartis India, told News18 in an email, “India’s aspiration to become a leading biopharmaceutical innovation hub will be strengthened by policies that provide confidence, predictability, and support for long-term research investment.”
Regulatory Data Protection, he said, is an established component of innovation ecosystems worldwide and helps safeguard the substantial investments required to generate clinical and regulatory data. “A globally competitive RDP framework would send a strong signal that India is ready to attract higher-value research, clinical development, and scientific partnerships, reinforcing its ambition to not only manufacture medicines for the world, but also help discover and develop the medicines of the future. Importantly, global experience shows that RDP and a strong generic medicines industry can coexist, supporting both innovation and access within a balanced healthcare ecosystem.”